URGENT:COVID prophylaxis | Vitamin D | Latest research | NIH | CDC | Worldometer
Saquinavir can cause transient and usually asymptomatic elevations in serum aminotransferase levels and, rarely, can lead to clinically apparent acute liver injury. In HBV or HCV coinfected patients, highly active antiretroviral therapy with saquinavir may result of an exacerbation of the underlying chronic hepatitis B or C.
Saquinavir (sa kwin' a vir) is an antiretroviral protease inhibitor that acts by binding to the catalytic site of the HIV protease, thereby preventing the cleavage of viral polyprotein precursors into mature, functional proteins that are necessary for viral replication.
Saquinavir was approved for use in the United States in 1995 and is still widely used in combination with other antiretroviral agents for the prevention and treatment of HIV infection in adults and children. Saquinavir is available under the brand name Invirase in 200 mg capsules and 500 mg tablets. It is usually used in combination with a low dose of ritonavir, which improves its pharmacokinetics and allows for twice daily dosing.
The recommended dose of saquinavir is 1000 mg in combination with 100 mg of ritonavir, both taken twice daily.
Drugs for HIV Infection, in the Subclass Antiretroviral Agents
- Nonnucleoside Reverse Transcriptase Inhibitors (HIV)
- Nucleoside Analogues (HIV)
- Protease Inhibitors (HIV)
HCV NS5A Inhibitors
HCV NS5B (Polymerase) Inhibitors
- Asunaprevir, Boceprevir, Glecaprevir, Grazoprevir, Paritaprevir, Simeprevir, Telaprevir, Voxilaprevir
Drugs for Herpes Virus Infections (HSV, CMV, others)
Drugs for Influenza